Video
Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC
Author(s):
In Partnership With:
Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.
Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates (ADCs) in the treatment of patients with triple-negative breast cancer (TNBC).
Isaacs predicts that a breakthrough is imminent in the treatment of TNBC, with positive data from phase II trials now being studied in phase III trials. ADCs target an antigen that is present in a fair proportion of patients with TNBC, and results are indicating benefit in heavily pre-treated patients with metastatic disease.
The ADC sacituzumab govitecan (IMMU-132) targets TROP-2, which is an antigen present in a significant proportion of patients with TNBC. In a recent study of 110 patients, treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic TNBC.
